Free tool
FAERS Monitor: Bicillin L-A
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050141 or its brand name (Bicillin L-A, Penicillin G Benzathine). Reports on generic versions are filed under their own applications.
Reports
1,363
Serious
496
36% of reports
Hospitalization
254
Death reported
39
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- recalled product administered573
- drug hypersensitivity67
- injection site pain63
- off label use45
- embolia cutis medicamentosa44
- pain43
- drug ineffective33
- acute kidney injury31
- rash28
- diarrhoea26
- no adverse event25
- headache24
- injection site swelling23
- pyrexia23
- foetal exposure during pregnancy21
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 6 |
| 2006 | 6 |
| 2007 | 4 |
| 2008 | 17 |
| 2009 | 8 |
| 2010 | 51 |
| 2011 | 24 |
| 2012 | 24 |
| 2013 | 13 |
| 2014 | 10 |
| 2015 | 20 |
| 2016 | 30 |
| 2017 | 36 |
| 2018 | 34 |
| 2019 | 86 |
| 2020 | 68 |
| 2021 | 39 |
| 2022 | 88 |
| 2023 | 62 |
| 2024 | 62 |
| 2025 | 622 |
| 2026 | 43 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,796 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| recalled product administeredSignal | 573 | 986.2 | 923.5 | 529,435 |
| embolia cutis medicamentosaSignal | 44 | 903.8 | 670.0 | 36,637 |
| drug hypersensitivitySignal | 67 | 5.3 | 4.2 | 234 |
| injection site swellingSignal | 23 | 4.6 | 3.1 | 62 |
| foetal exposure during pregnancySignal | 21 | 4.0 | 2.6 | 44 |
| injection site painSignal | 63 | 3.2 | 2.5 | 93 |
| acute kidney injurySignal | 31 | 3.1 | 2.2 | 43 |
| no adverse eventSignal | 25 | 2.1 | 1.4 | 14 |
| pain | 43 | 1.1 | 0.8 | 0 |
| pyrexia | 23 | 1.0 | 0.7 | 0 |
| rash | 28 | 1.0 | 0.7 | 0 |
| off label use | 45 | 0.8 | 0.6 | 2 |
| diarrhoea | 26 | 0.6 | 0.4 | 6 |
| headache | 24 | 0.6 | 0.4 | 7 |
| drug ineffective | 33 | 0.4 | 0.3 | 34 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.